FIELD: pharmaceuticals.
SUBSTANCE: invention refers to compounds of formula I-A: A1-L1-B1 and their pharmaceutically acceptable salts, where A1, B1 and L1 have values given in the claim. Compounds of formula I-A can be used to treat a condition or disorder responsive to destruction of MDM2 protein, such as cancer.
A1: 
,
B1: 
or 
.
EFFECT: in invention, MDM2 protein destructors are disclosed.
17 cl, 8 dwg, 9 tbl, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VET PROTEIN DECOMPOSERS | 2017 |
|
RU2752677C2 |
| CRYSTALS OF DIPYROPYRROLIDINE DERIVATIVES | 2013 |
|
RU2647840C2 |
| ISOINDOLINE COMPOUND, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND THEIR USE | 2019 |
|
RU2813232C2 |
| SPIRO OXINDOLE MDM2 ANTAGONISTS | 2010 |
|
RU2553269C2 |
| N- (PHENYLSULPHONYL) BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2744358C2 |
| N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | 2017 |
|
RU2722560C1 |
| ALDOSE REDUCTASE INHIBITORS AND METHODS OF THEIR APPLICATION | 2017 |
|
RU2795195C2 |
| DISPIROPYRROLIDINE DERIVATIVES | 2012 |
|
RU2612534C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| NEW DISPIRO-INDOLINONES, MDM2/p53 INTERACTION INHIBITORS, METHOD FOR PRODUCTION AND APPLICATION | 2015 |
|
RU2629750C2 |
